Ethical, scientific, and regulatory perspectives regarding the use of placebos in cancer clinical trials

Journal of Clinical Oncology

Volumn 26, Issue 8, 2008, Pages 1371-1378

  Daugherty, Christopher K ^a   Ratain, Mark J ^a   Emanuel, Ezekiel J ^a   Farrell, Ann T ^a   Schilsky, Richard L ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ATRASENTAN; CALCITRIOL; CELECOXIB; CETUXIMAB; ERLOTINIB; GEFITINIB; ISOTRETINOIN; LETROZOLE; MARIMASTAT; OREGOVOMAB; PLACEBO; PRINOMASTAT; REBIMASTAT; SIPULEUCEL T; SORAFENIB; SUNITINIB; TAMOXIFEN; TIPIFARNIB; UNCLASSIFIED DRUG;

ADD ON THERAPY; ARTICLE; CANCER RESEARCH; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDICATION; DRUG USE; HUMAN; MEDICAL ETHICS; PRIORITY JOURNAL; METHODOLOGY; NEOPLASM; REVIEW;

CLINICAL TRIALS AS TOPIC; ETHICS, MEDICAL; HUMANS; NEOPLASMS; PLACEBOS; RESEARCH DESIGN;

EID: 41649091413     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.13.5335     Document Type: Article

References (60)

1. Ratain MJ, Eckhardt SG: Phase II studies of modern drugs directed against new target: If you are fazed, too, then resist RECIST. J Clin Oncol 22:4442-4445, 2004
2. Goss PE, Ingle JN, Martino S, et al: Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA17. J Clin Oncol 25:2006-2011, 2007
3. Small EJ, Schellhammer PF, Higano CS, et al: Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone-refractory prostate cancer. J Clin Oncol 24:3089-3094, 2006
4. Smith MR, Manola J, Kaufman DS, et al: Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J Clin Oncol 24:2723-2728, 2006
5. Ratain MJ, Eisen T, Stadler WM, et al: Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24:2505-2512, 2006
6. Escudier B, Eisen T, Stadler WM, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134, 2007
7. Demetri GD, van Oosterom AT, Garrett CR, et al: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 368:1329-1338, 2006
8. Sparano JA, Berenardo P, Stephenson P, et al: Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group Trial E2196. J Clin Oncol 22:4683-4690, 2004
9. Rao S, Cunningham D, de Gramont A, et al: Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J Clin Oncol 19:3950-3957, 2004
10. Berek JS, Taylor PT, Gordon A, et al: Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J Clin Oncol 17:3507-3516, 2004
11. Carducci MA, Padley RJ, Breul J, et al: Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: A randomized, phase II, placebo-controlled trial. J Clin Oncol 21:679-689, 2003
12. Shepherd FA, Giaccone G, Seymour L, et al: Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: A trial of the National Cancer Institute of Canada Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 20:4434-4439, 2002
13. Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966, 2007
14. Gatzemeier U, Pluzanska A, Szczesna A, et al: Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial. J Clin Oncol 25:1545-1552, 2007
15. Giaccone G, Herbst RS, Manegold C, et al: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 1. J Clin Oncol 22:777-784, 2004
16. Herbst RS, Giaccone G, Schiller JH, et al: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2. J Clin Oncol 22:785-794, 2004
17. Beer TM, Tyan CW, Venner PM, et al: Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: A report from the ASCENT investigators. J Clin Oncol 25: 669-674, 2007
18. Richtig E, Soyer HP, Posch M, et al: Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group. J Clin Oncol 23:8655-8663, 2005
19. Burtness B, Goldwasser MA, Flood W, et al: Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 34: 8646-8654, 2005
20. Leighl NB, Paz-Ares L, Douillard J, et al: Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada Clinical Trials Group Study BR.18. J Clin Oncol 23:2831-2839, 2005
21. Bissett D, O'Byrne KJ, von Pawel J, et al: Phase III study of metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. J Clin Oncol 23:842-849, 2005
22. Van Cutsem E, van de Velde H, Karasek P, et al: Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 22:1430-1438, 2004
23. Fisher B, Bryant J, Dignam JJ, et al: Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol 20:4141-4149, 2002
24. Comis RL, Aldige CR, Stovall EL, et al: A Quantitative Survey of Public Attitudes Towards Cancer Clinical Trials. Coalition of National Cancer Cooperative Groups, Cancer Res Foundation of America, Cancer Leadership Council and Oncology Nursing Society, 2000. http://www.cancersummit.org/summit_meetings. htm
25. Access, Compassion, Care, and Ethics for Seriously Ill Patients Act (S. 1956). Introduced in the 109th Congress on November 3, 2005, by Sen. Sam Brownback (R-KS)
26. United States Food and Drug Administration: Expanded Access to Investigational Drugs for Treatment Use. Federal Register, Vol. 71, No. 240, December 14, 2006, Proposed Rules. http://www.fda.gov/OHRMS/DOCKETS/98fr/06- 9684.pdf
27. Rosner GL, Stadler W, Ratain MJ: Randomized discontinuation design: Application to cytostatic antineoplastic agents. J Clin Oncol 20:4478-4484, 2002
28. Freedman B: Equipoise and the ethics of clinical research. N Engl J Med 317:141-145, 1987
29. Levine RJ: Ethics and Regulation of Clinical Research (ed 2). New Haven, CT, Yale University Press, 1986
30. Hellman S, Hellman DS: Of mice but not men: Problems of the randomized clinical trial. N Engl J Med 324:1585-1589, 1991
31. Ashcroft R: Giving medicine a fair trial: Trials should not second guess what patients want. BMJ 320:1686, 2000
32. Freedman B: A response to a purported ethical difficulty with randomized clinical trials involving cancer patients. J Clin Ethics 3:231-234, 1992
33. Miller FG, Brody H: A critique of clinical equipoise: Therapeutic misconception in the ethics of clinical trials. Hastings Cent Rep 33:19-28, 2003
34. Freedman B, Glass KC, Weijer C: Placebo orthodoxy in clinical research I and II. J Law Med Ethics 24:243-251, 1996
35. Temple R, Ellenberg SS: Placebo-controlled trials and active control trials in the evaluation of new treatments: Part 1. Ethical and scientific issues. Ann Intern Med 133:455-463, 2000
36. Emanuel EJ, Miller FG: The ethics of placebo-controlled trials: A middle ground. N Engl J Med 345:915-919, 2001
37. World Medical Association: Declaration of Helsinki, 5th revision, 2000. http://www.wma.net/e/ethicsunit/helsinki.htm
38. Lie RK, Emanuel EJ, Grady C, et al: The standard of care debate: The Declaration of Helsinki versus the international consensus opinion. J Med Ethics 30:190-193, 2004
39. Cubeddu LX, Hoffmann IS, Fuenmayor NT, et al: Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med 322:810-816, 1990
40. Gandara DR, Harvey WH, Monaghan GG, et al: The delayed-emesis syndrome from cisplatin: Phase III evaluation of ondansetron versus placebo. Semin Oncol 19:67-71, 1992
41. Beck TM, Ciociola AA, Jones SE, et al: Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide based chemotherapy. Ann Intern Med 118:407-413, 1993
42. Hait WN: Ondansetron and cisplatin-induced nausea and vomiting. N Engl J Med 323:1485-1486, 1990
43. Gralla RJ, Itri LM, Pisko SE, et al: Antiemetic efficacy of high dose metoclopramide: Randomized trials with placebo and prochlorperazine in patients with chemotherapy induced nausea and vomiting. N Engl J Med 305:905-909, 1981
44. Joensuu H: Sunitinib for imatinib-refractory GIST. Lancet 368:1303-1304, 2006
45. Demetri GD, George S, Heinrich MC, et al: Clinical activity and tolerability of the multi-targeted tyrosine kinase inhibitor SU11248 in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) refractory to imatinib mesylate. Proc Am Soc Clin Oncol 22, 2003 (abstr 3273)
46. Amery W, Dony J: A clinical trial design avoiding undue placebo treatment. J Clin Pharmacol 15:674-679, 1975
47. Stadler WM, Rosner G, Small E, et al: Successful implementation of the randomized discontinuation trial design: An application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma-CALGB 69901. J Clin Oncol 23:3726-3732, 2005
48. United States Food and Drug Administration: FDA's Critical Path Initiative. http://www.fda.gov/oc/initiatives/criticalpath/woodcock/woodcock. html
49. The ATAC Trialists' Group: Anastrazole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 359:2131-2139, 2002
50. United States Code of Federal Regulations: Title 21-Food and Drugs. Part 314.500. Washington, DC, US Government Printing Office, 2005
51. United States Code of Federal Regulations: Title 21-Food and Drugs. Part 601.40. Washington, DC, US Government Printing Office, 2005
52. International Conference on Harmonization: Guidance for industry: Choice of Control and Related Issues in Clinical Trials. Geneva, Switzerland, International Conference on Harmonization, 2000, document E10
53. Ellenberg S, Temple R: Placebo-controlled trials and active-control trials in the evaluation of new treatments: Part 2. Practical issues and specific cases. Ann Intern Med 133:464-470, 2000
54. Johnson JR, Williams G, Pazdur R: End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 21:1404-1411, 2003
55. Ratain MJ, Karrison TG: Testing the wrong hypothesis in phase II oncology trials: There is a better alternative. Clin Cancer Res 13:781-782, 2007
56. United States Food and Drug Administration: Guidance for Industry: Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. May 2007. http://www.fda.gov/cder/guidance/7478fnl.pdf
57. Rothmann M, Li N, Chen G, et al: Design and analysis of non-inferiority mortality trials in oncology. Stat Med 22:239-264, 2003
58. Hazarika M, White R, Booth B, et al: Pemetrexed in malignant pleural mesothelioma. Clin Cancer Res 11:982-992, 2005
59. Kindler HL, Friberg G, Singh DA, et al: Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 23: 8033-8040, 2005
60. Kindler HL, Niedzwiecki D, Hollis D et al: A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB) 80303. J Clin Oncol 25, 2007 (suppl; abstr 4508)